$GNPX
Genprex Inc

2020 Q1 Form 10-Q Financial Statement

#000143774920010758 Filed on May 14, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.090M $1.660M
YoY Change 146.39% 163.49%
% of Gross Profit
Research & Development $1.478M $508.0K
YoY Change 190.9% 884.18%
% of Gross Profit
Depreciation & Amortization $5.353K $2.931K
YoY Change 82.63% 209.5%
% of Gross Profit
Operating Expenses $1.478M $508.0K
YoY Change 190.9% 884.18%
Operating Profit -$5.576M -$2.171M
YoY Change 156.88% 216.15%
Interest Expense $10.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.570M -$2.160M
YoY Change 157.87% 213.04%
Income Tax
% Of Pretax Income
Net Earnings -$5.566M -$2.159M
YoY Change 157.83% 211.07%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$199.3K -$140.8K
COMMON SHARES
Basic Shares Outstanding 32.85M 15.54M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.08M $6.950M
YoY Change 232.09% 34650.0%
Cash & Equivalents $23.08M $6.946M
Short-Term Investments
Other Short-Term Assets $70.00K $100.0K
YoY Change -30.0% 233.33%
Inventory $880.0K
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $24.03M $7.050M
YoY Change 240.88% 11972.54%
LONG-TERM ASSETS
Property, Plant & Equipment $50.71K $30.00K
YoY Change 69.04% 260.32%
Goodwill
YoY Change
Intangibles $535.9K $388.7K
YoY Change 37.89% 26.38%
Long-Term Investments
YoY Change
Other Assets $557.7K $404.8K
YoY Change 37.76% -69.32%
Total Long-Term Assets $608.4K $426.4K
YoY Change 42.68% -67.89%
TOTAL ASSETS
Total Short-Term Assets $24.03M $7.050M
Total Long-Term Assets $608.4K $426.4K
Total Assets $24.64M $7.476M
YoY Change 229.57% 439.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $640.0K $210.0K
YoY Change 204.76% -81.74%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $20.00K
YoY Change -100.0% -92.86%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $697.2K $231.1K
YoY Change 201.72% -83.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $697.2K $231.1K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $700.0K $230.0K
YoY Change 204.35% -83.92%
SHAREHOLDERS EQUITY
Retained Earnings -$46.05M -$31.98M
YoY Change 43.97% 76.25%
Common Stock $32.85K $15.56K
YoY Change 111.09% 32.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.94M $7.245M
YoY Change
Total Liabilities & Shareholders Equity $24.64M $7.476M
YoY Change 229.57% 439.27%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$5.566M -$2.159M
YoY Change 157.83% 211.07%
Depreciation, Depletion And Amortization $5.353K $2.931K
YoY Change 82.63% 209.5%
Cash From Operating Activities -$4.518M -$1.642M
YoY Change 175.16% 705.94%
INVESTING ACTIVITIES
Capital Expenditures $11.41K $4.111K
YoY Change 177.6% 179.85%
Acquisitions
YoY Change
Other Investing Activities -$80.00K
YoY Change
Cash From Investing Activities -$137.0K -$13.33K
YoY Change 927.78% 27.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $25.73M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.73M
YoY Change
NET CHANGE
Cash From Operating Activities -4.518M -1.642M
Cash From Investing Activities -137.0K -13.33K
Cash From Financing Activities 25.73M
Net Change In Cash 21.08M -1.655M
YoY Change -1373.45% 1110.19%
FREE CASH FLOW
Cash From Operating Activities -$4.518M -$1.642M
Capital Expenditures $11.41K $4.111K
Free Cash Flow -$4.529M -$1.646M
YoY Change 175.16% 702.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2010 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000
CY2018Q1 gnpx Capital Stock Shares Authorized
CapitalStockSharesAuthorized
210000000
CY2019 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
CY2020Q1 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
CY2019 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
CY2020Q1 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
CY2019 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
CY2020Q1 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
CY2019 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
CY2020Q1 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
CY2019 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0.46
CY2020Q1 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
CY2020Q1 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
0
CY2019 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
3611504
CY2020Q1 gnpx Investment Unit
InvestmentUnit
0
CY2019Q4 gnpx Investment Unit
InvestmentUnit
0
CY2019Q1 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
200
CY2020Q1 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
25731640
CY2018Q2 gnpx Nonvoting To Voting Common Stock Conversion Ratio
NonvotingToVotingCommonStockConversionRatio
1
CY2018Q2 gnpx Operating Lease Rent Expense Per Month
OperatingLeaseRentExpensePerMonth
2050
CY2020Q1 gnpx Payments To Acquire Research And Development Assets
PaymentsToAcquireResearchAndDevelopmentAssets
80857
CY2019Q1 gnpx Payments To Acquire Research And Development Assets
PaymentsToAcquireResearchAndDevelopmentAssets
CY2011 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000
CY2020Q1 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
882637
CY2019Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
801780
CY2010Q4 gnpx State Of Texas Emerging Technology Fund Award Amount
StateOfTexasEmergingTechnologyFundAwardAmount
4500000
CY2020Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
638392
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
436258
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69955788
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43483740
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
522700
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
752444
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
750000
CY2020Q1 us-gaap Assets
Assets
24640185
CY2019Q4 us-gaap Assets
Assets
3534229
CY2020Q1 us-gaap Assets Current
AssetsCurrent
24031796
CY2019Q4 us-gaap Assets Current
AssetsCurrent
2976643
CY2020Q1 us-gaap Cash
Cash
23079591
CY2019Q4 us-gaap Cash
Cash
2002492
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2002492
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8600918
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23079591
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6945794
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21077099
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1655124
CY2020Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
22829591
CY2019Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1761278
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.36
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.45
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.45
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3864552
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7476056
CY2020Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7476056
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32849841
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19263841
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32849841
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19263841
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
32850
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
19264
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
5576226
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
2170769
CY2020Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
21732
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
21732
CY2020Q1 us-gaap Depreciation
Depreciation
5353
CY2019Q1 us-gaap Depreciation
Depreciation
2931
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5300000
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2013Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2500000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4092996
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1659796
CY2020Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2019Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
202134
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-88818
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-655
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9297
CY2020Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
CY2019Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-1950
CY2020Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-15592
CY2019Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-67922
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-102148
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-136593
CY2020Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
535944
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
491200
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
10006
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
11923
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24640185
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3534229
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
697226
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
510684
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25731640
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-137013
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13331
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4517528
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1641793
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5566220
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2158846
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5576226
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2170769
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
557676
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
512932
CY2020Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
58834
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
74426
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
44744
CY2019Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9220
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11412
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4111
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
69568
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
171716
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25731640
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50713
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44654
CY2020Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
655
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1477877
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
508042
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46045679
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40479459
CY2020Q1 us-gaap Revenues
Revenues
CY2019Q1 us-gaap Revenues
Revenues
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
753994
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
523022
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
297058
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
297058
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1165325
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1744300
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7148248
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4535681
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5982923
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.31
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.66
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.55
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.48
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y233D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y164D
CY2020Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
5000
CY2019 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
506707
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1550
CY2019 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
469588
CY2019Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
122
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
23942959
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3023545
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
8881135
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
7245311
CY2018Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
6.6841954
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of our condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div>
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27952742
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15335772

Files In Submission

Name View Source Status
0001437749-20-010758-index-headers.html Edgar Link pending
0001437749-20-010758-index.html Edgar Link pending
0001437749-20-010758.txt Edgar Link pending
0001437749-20-010758-xbrl.zip Edgar Link pending
ex_173126.htm Edgar Link pending
ex_173127.htm Edgar Link pending
ex_173128.htm Edgar Link pending
ex_186626.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gnpx-20200331.xml Edgar Link completed
gnpx-20200331.xsd Edgar Link pending
gnpx-20200331_cal.xml Edgar Link unprocessable
gnpx-20200331_def.xml Edgar Link unprocessable
gnpx-20200331_lab.xml Edgar Link unprocessable
gnpx-20200331_pre.xml Edgar Link unprocessable
gnpx20200331_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending